Table 1.
Characteristics of included case reports
| Study, year | Age (years) | Sex | Length of colchicine Therapy | Dose/day (mg) | Co-administered agents | Presenting symptoms | Time from first concurrent drug dose to symptoms (days) | Laboratory data | Time to resolution | |
|---|---|---|---|---|---|---|---|---|---|---|
| CK (U/L) | AST/ALT (U/L) | |||||||||
| Mckinnell et al., 2009 [4] | 48 | M | Long-term use | 0.6 | Clarithromycin | Severe muscle pain | 3 | 22,996 | 513/182 | 4 days |
| van der Velden et al., 2008 [5] | 73 | M | 1 year | 0.5 | Clarithromycin | Muscle weakness, fatigue | 10 | 1396 | 219/345 | 14 days |
| Alayli et al., 2005 [6] | 65 | F | NR | 1.5 | Pravastatin | Proximal muscle weakness | 20 | 914 | 149/120 | 7 days |
| Bouquié et al., 2011 [7] | 34 | M | 8 days | Day 1: 3 mg Day 2–3: 2 mg Day4–8: 1 mg |
Pravastatin Azithromycin Cyclosporine |
Multiple organ failure rhabdomyolysis | 8 | 3206 | 122/136 | 11 days |
| Hsu et al., 2002 [8] | 70 | F | NR | 1 | Simvastatin | Proximal muscle weakness | 14 | 918 | AST:107 | 14 days |
| Oh et al., 2012 [9] | 84 | M | NR | 1 mg qd for 3 days, then 0.5 mg qd | Simvastatin | Proximal muscle weakness | 21 | 2837 | NR | 56 days |
| Francis et al., 2008 [10] | 66 | M | NR | 1.2 | Simvastatin | Muscle weakness | NR | 2538 | NR | |
| Baker et al., 2004 [11] | 79 | M | NR | 1.2 | Simvastatin | Severe muscle proximal weakness | 8 | 32,040 | NR | 14 days |
| Justiniano et al., 2007 [12] | 61 | F | NR | 1.2 | Simvastatin | Muscle weakness | 12 | 6765 | NR | 14 days |
| Sahin et al., 2008 [13] | 30 | M | Long-term use | 1.5 | Simvastatin | Muscle pain, proximal muscle weakness and cramps | 21 | 1232 | 67/71 | 14 days |
| Atasoyu et al., 2005 [14] | 70 | M | NR | 1.5 | Fluvastatin | Arms and legs weakness, severe pains | 3 | 37782 | AST:856 | 19 days |
| Sarullo et al., 2010 [15] | 77 | M | NR | 1 | Fluvastatin | Arms pain, legs weakness | 14 | 2371 | 617/523 | 16 days |
| Atmaca et al., 2002 [16] | 40 | M | 3 years | 1.5 | Gemfibrozil | Muscle pain | 14 | 3559 | 232/165 | 9 days |
| Tufan et al., 2006 [17] | 45 | M | 3 years | 1.5 | Atorvastatin | Lower extremity weakness, muscle pain, gait instability | 14 | 9035 | 513/72 | 10 days |
| Sahin et al., 2008 [13] | 43 | M | 2 months | 1.5 | Atorvastatin | Muscle pain and proximal muscle weakness | 14 | 608 | 38/24 | 21 days |
| Sahin et al., 2008 [13] | 30 | M | Long-term use | 1 | Atorvastatin | Muscle pain and proximal muscle weakness | 20 | 11,069 | 342/347 | 7 days |
| Torgovnick et al, 2006 [18] | 74 | M | NR | NR | Lovastatin | Proximal muscle weakness | 28 | 8370 | NR | Several weeks |
| Lee et al., 1997 [19] | 49 | M | NR | 2.4 | Cyclosporine | Mild muscle weakness in the lower extremities | 3 | 14958 | 561/403 | 14 days |
| Gruberg et al., 1999 [20] | 53 | M | NR | 1.5 | Cyclosporine | Muscle pain and weakness | NR | 3003 | 141/90 | 14 days |
| Eleftheriou et al., 2008 [21] | 60 | M | NR | 1 | Cyclosporine | Myalgia, vomiting, diarrhea | 6 | 658 | 775/376 | 27 days |
| Garrouste et al., 2012 [22] | 59 | M | 7 days | 3 | Cyclosporine | Abdominal pain with mucous diarrhea Myalgia |
5 | 4116 | 166/105 | 30 days |
| Rana et al., 1997 [23] | 53 | M | 6 months | 0.6 | Cyclosporine | Proximal weakness | NR | >3000 | NR | 7 days |
| Rana et al., 1997 [23] | 56 | M | NR | NR | Cyclosporine | Malaise, fatigue, generalized weakness | NR | 449 | NR | A few weeks |
| Rana et al., 1997 [23] | 57 | F | NR | NR | Cyclosporine | Generalized weakness, distal extremity paresthesia | NR | 721 | NR | 30 days |
ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, F female, M male, NR not reported